MRTX1133 manufacturers
- MRTX1133
-
- $0.00 / 100MG
-
2024-05-31
- CAS:2621928-55-8
- Min. Order: 1MG
- Purity: 98
- Supply Ability: 100G
|
| | MRTX1133 Basic information |
| Product Name: | MRTX1133 | | Synonyms: | 2-Naphthalenol, 4-[4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-8-fluoro-2-[[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoro-;4-(4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,7aS)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol;MRTX1133;4-[4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-[[(2S,7aS)-2-fluorohexahydro-1H-pyrrolizin-7a-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol;KRAS,Ras,MRTX 1133,G12D,cells,active,wild-type,phosphorylation,mutant,MRTX1133,inactive,ERK,inhibit,tumor,states,MRTX-1133,Inhibitor;4-[4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-8-fluoro-2-[[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoro-2-Naphthalenol | | CAS: | 2621928-55-8 | | MF: | C33H31F3N6O2 | | MW: | 600.63 | | EINECS: | | | Product Categories: | | | Mol File: | 2621928-55-8.mol |  |
| | MRTX1133 Chemical Properties |
| density | 1.49±0.1 g/cm3(Predicted) | | solubility | DMSO:50.0(Max Conc. mg/mL);83.24(Max Conc. mM) | | form | A solid | | pka | 8.05±0.40(Predicted) | | InChIKey | SCLLZBIBSFTLIN-IFMUVJFISA-N | | SMILES | C1=C2C(C(C#C)=C(F)C=C2)=C(C2N=CC3=C(N4CC5NC(CC5)C4)N=C(OC[C@]45C[C@@H](F)CN4CCC5)N=C3C=2F)C=C1O |
| | MRTX1133 Usage And Synthesis |
| Uses | MRTX1133 is a potent and selective KRAS G12D inhibitor that targets KRAS G12D protein in both the active and inactive states. In preclinical studies, MRTX1133 exhibited a long half-life, was able to bind to KRAS G12D protein in both active and inactive states, and selectively inhibited KRAS G12D-mutated cancer cells. In G12D mutant tumor models, it showed dose-dependent selective inhibition of the KRAS pathway and tumor regression. | | Chemical Properties | Solid powder. | | Biological Functions |
MRTX1133 is a noncovalent, potent, and selective KRAS G12D inhibitor. It optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. This inhibitor selectively inhibits KRAS G12D mutants but not KRAS wild-type tumor cells. MRTX1133 has single-digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations.
| | target | KRas G12D | | storage | Dry, dark and at 0-4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| | MRTX1133 Preparation Products And Raw materials |
|